机器人与腹腔镜胃癌根治术治疗cI/II期胃癌的三年结局:多中心回顾性对比研究
本研究为多中心回顾性研究,比较机器人胃切除术(RG)与腹腔镜胃切除术(LG)治疗cStage I/II胃癌的3年结局。经倾向评分逆概率加权后,RG组3年总生存率显著优于LG组(96.3% vs 89.6%,HR 0.34,p=0.009),但3年无复发生存率无差异;RG未改善总并发症率,但减少了吻合口漏和腹腔脓肿等不良事件。
要点
- RG组3年总生存率显著高于LG组(96.3% vs 89.6%,HR 0.34,p=0.009)。
- 两组3年无复发生存率无显著差异(HR 0.58,p=0.073)。
- pStage IA亚组中RG改善3yOS和3yRFS(HR均为0.05)。
核心结论
- 对于cStage I/II胃癌,RG在3年结局上显示出与LG相当的手术和肿瘤学安全性。
研究设计与样本
- 多中心回顾性研究,纳入先前前瞻性研究(UMIN000015388)中接受RG的患者及接受LG的历史对照。
- 共326例RG和752例LG患者完成研究,采用倾向评分逆概率加权平衡人口学因素和外科医生手术量。
主要发现
- 加权后RG组3年总生存率为96.3%,LG组为89.6%(HR 0.34 [0.15, 0.76];p=0.009)。
- 两组3年无复发生存率无差异(HR 0.58 [0.32, 1.05];p=0.073)。
- pStage IA亚组中,RG改善3yOS(HR 0.05 [0.01, 0.38];p=0.004)和3yRFS(HR 0.05 [0.01, 0.34];p=0.003)。
- RG组和LG组的复发率和复发模式相似。
- RG未改善并发症率,但减少了吻合口漏和腹腔脓肿等部分不良事件,并改善了估计失血量和术后住院时间。
临床怎么用
- 对于cStage I/II胃癌,RG可作为LG的替代选择,尤其可能改善总生存。
- RG可能减少吻合口漏和腹腔脓肿等特定并发症,并缩短住院时间。
局限性
- 本研究为回顾性设计,LG组为历史对照,可能存在选择偏倚。
- RG组样本量较小(326例),需进一步前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oncological benefits of robotic gastrectomy (RG) remain unclear. We aimed to determine and compare the 3-year outcomes of RG and laparoscopic gastrectomy (LG) for the treatment of gastric cancer. METHODS: This was a multi-institutional retrospective study of patients who prospectively underwent RG in a previous study (UMIN000015388) and historical controls who underwent LG. Operable patients with cStage I/II primary gastric cancer were enrolled. The inverse probability of treatment weighting method based on propensity scores was used to balance patient demographic factors and surgeon volume between the RG and LG groups. The primary outcome measure was the 3-year overall survival rate (3yOS). RESULTS: Of the 1,127 patients in the previous study, 326 and 752 patients in the RG and LG groups, respectively, completed the study. The standardized difference of all confounding factors was reduced to 0.09 or less after weighting. In the weighted population, 3yOS was 96.3% and 89.6% in the RG and LG groups, respectively (hazard ratio [HR] 0.34 [0.15, 0.76]; p = 0.009), whereas there was no difference in 3-year recurrence-free survival rate (3yRFS) between the two groups (HR 0.58 [0.32, 1.05]; p = 0.073). Sub-analyses showed that RG improved 3yOS (HR 0.05 [0.01, 0.38]; p = 0.004) and 3yRFS (HR 0.05 [0.01, 0.34]; p = 0.003) in patients with pStage IA disease. Recurrence rates and patterns were similar between the RG and LG groups. RG did not improve the morbidity rate, however, it attenuated some of the adverse events, including anastomotic leakage and intra-abdominal abscess. RG improved estimated blood loss and duration of postoperative hospitalization. CONCLUSION: This study showed surgical and oncological safety of RG for cStage I/II gastric cancer considering the 3-year outcomes, compared with those of LG.
引用
- Suda K, Sakai M, Obama K, et al. Three-year outcomes of robotic gastrectomy versus laparoscopic gastrectomy for the treatment of clinical stage I/II gastric cancer: a multi-institutional retrospective comparative study. Surg Endosc. 2022. PMID: 36484859. doi:10.1007/s00464-022-09802-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。